ImmuPharma (LON:IMM) Stock Price Up 17.2% – What’s Next?

ImmuPharma plc (LON:IMM)’s share price shot up 17.2% on Wednesday . The company traded as high as GBX 15.15 ($0.20) and last traded at GBX 13.04 ($0.18). 47,707,926 shares changed hands during trading, an increase of 514% from the average session volume of 7,768,032 shares. The stock had previously closed at GBX 11.13 ($0.15).

ImmuPharma Price Performance

The business has a 50 day moving average price of GBX 2.55 and a 200 day moving average price of GBX 2.76. The firm has a market capitalization of £65.96 million, a P/E ratio of -1,483.15 and a beta of 1.53.

ImmuPharma (LON:IMM) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.